Active Motif Arima Genomics distribution deal
Analysis based on 7 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The distribution agreement strengthens Active Motif's product portfolio in the growing spatial genomics market, potentially increasing its revenue and market share. For Arima Genomics, the deal allows it to focus on its clinical diagnostics platform while leveraging Active Motif's distribution network for research products, which may accelerate its path to profitability.
Active Motif, a provider of epigenetics and multiomic solutions, announced an exclusive global commercial distribution agreement with Arima Genomics, a cancer diagnostics company. Under the agreement, Active Motif becomes the exclusive worldwide distributor of Arima's Hi-C products and services for research applications, while Arima focuses on its Aventa clinical diagnostics platform. The deal, effective immediately, combines Arima's 3D genomics technology with Active Motif's global commercial infrastructure and scientific expertise, enabling broader access for academic, pharmaceutical, biotechnology, and clinical research organizations. The partnership reflects growing demand for 3D genome mapping technologies in cancer, neuroscience, and precision medicine research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard